Melanoma cutâneo ainda constitui a principal causa de morte por câncer de pele nos países desenvolvidos. A variabilidade do comportamento clínico dessa neoplasia tem sido apenas parcialmente explicada pelos aspectos clínicos e histológicos, e a identificação de variáveis biológicas pode vir a ser importante na determinação de grupos de risco específicos. Foram estudados 69 pacientes com melanoma cutâneo primário de diversos graus de gravidade, tratados entre 1990 e 2007, com o intuito de verificar aspectos clínicos e epidemiológicos, preparar Tissue microarray (TMA) para estudo dos melanomas cutâneos primários com espessura maior que 1,0 mm, avaliar por análise imuno-histoquímica a expressão das proteínas da apoptose celular Bcl2, Bax, Bak, Apaf-1, Caspase 3, Caspase 9, Caspase 8, FasL e Fas em nevos-controle e em melanomas primários com espessuras menores e maiores que 1mm, e correlacionar a expressão dessas proteínas da apoptose com a evolução de melanomas cutâneos primários. Os resultados ratificaram tanto dados epidemiológicos já publicados em relação a sexo, idade e local da lesão, quanto a correlação entre a evolução da doença e os índices de Breslow. A análise dos escores compostos relativos à expressão das proteínas da apoptose revelou que o perfil imuno-histoquímico dessas proteínas parece não ter significado prognóstico, uma vez que não houve diferenças de expressão entre pacientes com e sem doença disseminada. Não foram encontradas alterações na expressão das proteínas da apoptose estudadas que pudessem sugerir o seu envolvimento tanto na gênese quanto na progressão de melanoma primário. O perfil imuno-histoquímico com tendência pró-apoptótica parece indicar que outros fatores seriam responsáveis pelo crescimento e disseminação da neoplasia / Cutaneous melanoma still constitutes the main cause of skin cancer death in developed world. Clinical behavior variability of this neoplasia has been only partially explained by clinical and histological aspects, and identification of biological variables can be important for determining specific risk groups. Sixty nine (69) patients with mild to severe primary cutaneous melanoma treated in 1990-2007 were studied aiming at (a) verifying clinical epidemiological aspects, (b) generating a Tissue microarray (TMA) for characterizing proteins expression of cutaneous melanoma > 1.0 mm, (c) analyzing the immunohistochemical expression of the apoptosis proteins Bcl2, Bax, Bak, Apaf-1, Caspase 3, Caspase 9, Caspase 8, FasL e Fas in 10 control nevi and in primary melanomas with thickness 1mm, (d) and correlating these proteins expression with the disease prognosis. Results have ratified known epidemiological date on gender, age and lesion localization as well as the correlation between the disease prognosis and the Breslow\'s indexes. Analysis of the composite scores relating to apoptosis proteins has revealed that their immunohistochemical profile seems to be not significant for determining the disease prognosis, since no differences in proteins expression were found when compared patients with and without disease dissemination. Alterations in proteins expression suggesting their role in the genesis as well as in the prognosis of primary melanoma were not evidenced. Immunohistochemical profile with pro-apoptosis trend seems to indicate other factor as responsible for the neoplasia growth and dissemination

Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2014-09-24T14:56:36Z No. of bitstreams: 2 Cysneiros, Maria Auxiliadora de Paula Carneiro.pdf: 1396665 bytes, checksum: f26660692713226fc47ed6704e9d53a9 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Cláudia Bueno (claudiamoura18@gmail.com) on 2014-09-28T02:03:10Z (GMT) No. of bitstreams: 2 Cysneiros, Maria Auxiliadora de Paula Carneiro.pdf: 1396665 bytes, checksum: f26660692713226fc47ed6704e9d53a9 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-09-28T02:03:10Z (GMT). No. of bitstreams: 2 Cysneiros, Maria Auxiliadora de Paula Carneiro.pdf: 1396665 bytes, checksum: f26660692713226fc47ed6704e9d53a9 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2013-10-16 / Endocervical and Endometrial Adenocarcinomas are uterine neoplasms with different biological behaviors and different treatments, being all the therapeutic plan based on the origin site of these tumors. To differentiate these two neoplasms, many times the immunohistochemical study is used as an ancillary tool to assist and complement histopathological examination. Previous studies have investigated the value of various markers in the distinction of these neoplasms, with results varying and sometimes conflicting. In this study the impact of the MCM2, bcl2 and villin markers in the differential diagnosis of endocervical and endometrial adenocarcinomas, associated or not to a traditional markers panel formed by CEA, vimentin, RE, RP and p16, was evaluated. Material and methods: A tissue microarray (TMA) was constructed using paraffin-embedded, formalin-fixed tissues from 104 hysterectomy specimens and conizations. Out of the 104, 51 samples were represented by unequivocal cases of adenocarcinomas of the endocervice and 53 represented unequivocal cases of endometrial adenocarcinomas. The sections of tissue microarray block were immunostained with the eight antibodies in study and to the antigen-antibody reaction preview it was used the polymer detection system. Scoring of immunostaining was interpreted using the German semi quantitative scoring system in considering the staining intensity and area extent of marker expression. The final Immunoreactive score was determined by multiplying the positive intensity and the positive area extent scores. The threshold for differentiating between final positive and negative immunostaining was set at 4 for interpretation (0-3 = negative; 4-12 = positive). Results: The univariate analysis showed that out of the eight markers, seven (CEA, vimentin, RE, RP, p16, MCM2 and bcl2) showed good performance in the distinction between the endocervical and endometrial origin. The multivariate analysis showed that CEA, p16 and MCM2 were the strongest predictors of site of origin. In the evaluation of six panels built by various combinations of immunomarkers , the panel with the lowest accuracy was that represented by MCM2, bcl2 and villin. The villin did not show any statistically significant difference in the differential diagnosis of these adenocarcinomas. Despite the MCM2 and bcl2 have revealed significant differences of frequency between the two sites of origin, they did not demonstrate additional benefit when added to a traditional panel. Conclusion: According to our study, the inclusion of MCM2, bcl2 and villin in the immunohistochemical assessment of uterine adenocarcinomas, added no supplementary value in the differentiation of these two neoplasms. / Adenocarcinomas endocervicais e endometriais são neoplasias uterinas com comportamentos biológicos e tratamentos distintos, sendo todo o plano terapêutico baseado no sítio de origem desses tumores. Para diferenciação dessas duas neoplasias, muitas vezes utiliza-se o estudo imuno-histoquímico como ferramenta auxiliar e complementar ao exame histopatológico. Prévios estudos têm investigado o valor de diferentes marcadores na distinção dessas neoplasias, com resultados variáveis e, por vezes, conflitantes. Neste estudo foi avaliado o desempenho dos marcadores MCM2, bcl2 e vilina no diagnóstico diferencial desses adenocarcinomas, associados ou não a um painel de marcadores tradicionais formados por CEA, vimentina, RE, RP e p16. Material e métodos: Um microarranjo de tecido (TMA) foi construído usando tecidos fixados em formol e embebidos em parafina, a partir de 104 amostras provenientes de histerectomias e conizações. Das 104 amostras, 51 eram representadas por casos inequívocos de adenocarcinomas de endocérvice e 53 representavam casos inequívocos de adenocarcinomas de endométrio. As secções do bloco de TMA foram imunomarcadas com os oito anticorpos em estudo e para vizualização da reação antígeno-anticorpo foi utilizado o sistema de detecção com polímeros. A marcação imuno-histoquímica foi graduada de acordo com o sistema semi-quantitativo alemão, levando-se em consideração a intensidade de marcação e a extensão de células marcadas. O score de imunorreatividade final foi determinado pela multiplicação da intensidade pela extensão de marcação. Um limite de corte de 4 foi determinado para diferenciação entre um resultado final positivo ou negativo (0- 3= negativo; 4- 12= positivo). Resultados: Análise univariada mostrou que dos oito marcadores avaliados, sete (CEA, vimentina, RE, RP, p16, MCM2 e bcl2) apresentaram bom desempenho na distinção entre origens endocervical e endometrial da neoplasia. Análise multivariada mostrou que CEA, p16 e MCM2 foram os mais fortes preditores do sítio anatômico. Na avaliação dos seis painéis construídos por combinações variadas desses marcadores, o painel com menor acurácia diagnóstica foi o representado por MCM2, bcl2 e vilina. A vilina não apresentou nenhuma diferença estatisticamente significativa no diagnóstico diferencial desses adenocarcinomas. Apesar do MCM2 e bcl2 terem revelado diferenças significativas de frequência entre os dois sítios de origem, eles não demonstraram valor suplementar quando adicionados a um painel tradicional. Conclusão: De acordo com este estudo, a inclusão de MCM2, bcl2 e vilina em um painel tradicional de 5 marcadores (CEA, vimentina, RE, RP, p16), não agregou nenhum benefício adicional na distinção imuno-histoquímica do sítio de origem desses adenocarcinomas uterinos.

Melanoma cutâneo ainda constitui a principal causa de morte por câncer de pele nos países desenvolvidos. A variabilidade do comportamento clínico dessa neoplasia tem sido apenas parcialmente explicada pelos aspectos clínicos e histológicos, e a identificação de variáveis biológicas pode vir a ser importante na determinação de grupos de risco específicos. Foram estudados 69 pacientes com melanoma cutâneo primário de diversos graus de gravidade, tratados entre 1990 e 2007, com o intuito de verificar aspectos clínicos e epidemiológicos, preparar Tissue microarray (TMA) para estudo dos melanomas cutâneos primários com espessura maior que 1,0 mm, avaliar por análise imuno-histoquímica a expressão das proteínas da apoptose celular Bcl2, Bax, Bak, Apaf-1, Caspase 3, Caspase 9, Caspase 8, FasL e Fas em nevos-controle e em melanomas primários com espessuras menores e maiores que 1mm, e correlacionar a expressão dessas proteínas da apoptose com a evolução de melanomas cutâneos primários. Os resultados ratificaram tanto dados epidemiológicos já publicados em relação a sexo, idade e local da lesão, quanto a correlação entre a evolução da doença e os índices de Breslow. A análise dos escores compostos relativos à expressão das proteínas da apoptose revelou que o perfil imuno-histoquímico dessas proteínas parece não ter significado prognóstico, uma vez que não houve diferenças de expressão entre pacientes com e sem doença disseminada. Não foram encontradas alterações na expressão das proteínas da apoptose estudadas que pudessem sugerir o seu envolvimento tanto na gênese quanto na progressão de melanoma primário. O perfil imuno-histoquímico com tendência pró-apoptótica parece indicar que outros fatores seriam responsáveis pelo crescimento e disseminação da neoplasia / Cutaneous melanoma still constitutes the main cause of skin cancer death in developed world. Clinical behavior variability of this neoplasia has been only partially explained by clinical and histological aspects, and identification of biological variables can be important for determining specific risk groups. Sixty nine (69) patients with mild to severe primary cutaneous melanoma treated in 1990-2007 were studied aiming at (a) verifying clinical epidemiological aspects, (b) generating a Tissue microarray (TMA) for characterizing proteins expression of cutaneous melanoma > 1.0 mm, (c) analyzing the immunohistochemical expression of the apoptosis proteins Bcl2, Bax, Bak, Apaf-1, Caspase 3, Caspase 9, Caspase 8, FasL e Fas in 10 control nevi and in primary melanomas with thickness 1mm, (d) and correlating these proteins expression with the disease prognosis. Results have ratified known epidemiological date on gender, age and lesion localization as well as the correlation between the disease prognosis and the Breslow\'s indexes. Analysis of the composite scores relating to apoptosis proteins has revealed that their immunohistochemical profile seems to be not significant for determining the disease prognosis, since no differences in proteins expression were found when compared patients with and without disease dissemination. Alterations in proteins expression suggesting their role in the genesis as well as in the prognosis of primary melanoma were not evidenced. Immunohistochemical profile with pro-apoptosis trend seems to indicate other factor as responsible for the neoplasia growth and dissemination

The EWSR1-FLI1 t(11;22)(q24;q12) translocation is the pathognomonic genomic alteration in 85% of the Ewing Family of Tumors (EWFT) a malignancy of the bone and the surrounding tissue, predominantly affecting children and adolescents. This translocation results in the formation of a chimeric oncoprotein which acts as an aberrant transcription factor that is currently not pharmaceutically druggable, driving the need for more effective targeted therapies. The EWSR1-FLI1 translocation induces a variety of changes including dysregulation of the epigenome and altered gene expression to drive tumorigenesis, and consequently contributes to the hypersensitivity of EWFT to several classes of chemotherapeutics. We sought to exploit these intrinsic sensitivities by employing a matched pair of cell lines derived from the same patient with Ewing sarcoma prior to and following chemotherapy, a panel of Ewing sarcoma cell lines, and several patient-derived xenografts (PDX) collected at the time of relapse or autopsy, which led us to the development of two novel combination targeted therapies for EWFT. In our matched pair of EWFT cell lines, we found sensitivity to the Poly(ADP-ribose Polymerase (PARP) inhibitor olaparib was diminished following chemotherapy, despite a predicted sensitivity. In addition, we discovered increased expression of the antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic resistance to olaparib. We found that EWS-FLI1 increases BCL-2 expression; however, inhibition of BCL-2 alone is insufficient to sensitize EWFT cells to olaparib, revealing a dual necessity for BCL-2 and BCL-XL (BCL2L1) in EWFT survival. These data reveal BCL-2 and BCL-XL act together to drive olaparib mediated apoptotic resistance in Ewing sarcoma and identify a novel, rational combination therapy using olaparib and the BCL-2/BCL-XL inhibitor navitoclax. In addition, using high throughput drug screening we have identified a novel epigenetic susceptibility in EWFT to GSK-J4 (GlaxoSmithKline), an inhibitor of lysine 27 of histone 3 (H3K27) demethylases: ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX) and Jumonji D3 (JMJD3). Treatment with GSK-J4 leads to a decrease in H3K27 acetylation (H3K27ac) and ultimately, the silencing of EWS-FLI1 gene targets. We sought to sensitize GSK-J4-mediated inhibition of EWS-FLI1 targets by blocking RNA polymerase II activity using the Cyclin Dependent Kinase 7 (CDK7) inhibitor THZ1. By targeting CDK7-mediated transcription we were able to sensitize EWFTs to H3K27 demethylase inhibition. We therefore propose co-targeting of H3K27 demethylases and CDK7 acts as a surrogate EWS-FLI1 inhibitor. Given the difficulties targeting EWS-FLI1, these strategies may present viable clinical therapies.

Macrophages represent long lived immune cells that are remarkably resistant to apoptosis, which allows them to perform in highly stressful environments. Apoptosis resistance is a characteristic that develops during the differentiation process from monocytes to macrophages. However, the signaling pathways that mediate the development of macrophage antiapoptotic phenotype during differentiation remain mostly unknown. Because of their decreased susceptibility to cell death, macrophages are also key viral reservoirs during HIV infection. My research aims to understand the molecular mechanisms and signaling pathways that mediate cell survival during and after monocyte to macrophage differentiation and the involvement of the main families of antiapoptotic proteins, IAPs (inhibitors of apoptosis) and Bcl2 in this process. HIV accessory protein Vpr was used as an apoptotic stimulus, due to its death inducing abilities in other cell types. My results show that survival of macrophages is distinctively regulated during and after differentiation. I have identified a signaling pathway consisting of PI3K/Akt activation of NFκB that is important in survival of differentiating macrophages by specifically sustaining antiapoptotic Bcl-xL expression. However, once differentiated, Mcl-1, but not Bcl-xL is dependent on PI3K/Akt activation. Moreover, differentiated macrophages are resistant to the effect of HIV-Vpr, which is highly apoptotic for monocytes. In contrast, resistance to HIV-Vpr induced apoptosis of human macrophages is specifically mediated by antiapoptotic IAP proteins, with no involvement of the Bcl2 family, which maintains macrophage viability in the absence of any apoptotic stimuli. In addition to their antiapoptotic properties, IAPs are also important regulators of macrophage function. By using chemical compounds (SMAC mimetics) that target IAPs for degradation, I have shown that IAPs positively modulate LPS-induced IL10, IL-27 and MIG (monokine induced by IFNγ) production in human macrophages, by promoting TRAF2, JNK and p38 signaling and NFκB activation. In addition, IAPs also contribute to LPS-induction of CD80/CD86 costimulatory molecules. Overall, my results suggest that both IAPs and Bcl2 families contribute to survival of human macrophages and that IAPs are also involved in innate immune responses. Unraveling the mechanisms that control macrophage survival and function in various settings would provide therapeutic strategies aimed at eliminating cells when their survival is no longer beneficial for the host, as in the case of HIV infection or autoimmune diseases.

Macrophages represent long lived immune cells that are remarkably resistant to apoptosis, which allows them to perform in highly stressful environments. Apoptosis resistance is a characteristic that develops during the differentiation process from monocytes to macrophages. However, the signaling pathways that mediate the development of macrophage antiapoptotic phenotype during differentiation remain mostly unknown. Because of their decreased susceptibility to cell death, macrophages are also key viral reservoirs during HIV infection. My research aims to understand the molecular mechanisms and signaling pathways that mediate cell survival during and after monocyte to macrophage differentiation and the involvement of the main families of antiapoptotic proteins, IAPs (inhibitors of apoptosis) and Bcl2 in this process. HIV accessory protein Vpr was used as an apoptotic stimulus, due to its death inducing abilities in other cell types. My results show that survival of macrophages is distinctively regulated during and after differentiation. I have identified a signaling pathway consisting of PI3K/Akt activation of NFκB that is important in survival of differentiating macrophages by specifically sustaining antiapoptotic Bcl-xL expression. However, once differentiated, Mcl-1, but not Bcl-xL is dependent on PI3K/Akt activation. Moreover, differentiated macrophages are resistant to the effect of HIV-Vpr, which is highly apoptotic for monocytes. In contrast, resistance to HIV-Vpr induced apoptosis of human macrophages is specifically mediated by antiapoptotic IAP proteins, with no involvement of the Bcl2 family, which maintains macrophage viability in the absence of any apoptotic stimuli. In addition to their antiapoptotic properties, IAPs are also important regulators of macrophage function. By using chemical compounds (SMAC mimetics) that target IAPs for degradation, I have shown that IAPs positively modulate LPS-induced IL10, IL-27 and MIG (monokine induced by IFNγ) production in human macrophages, by promoting TRAF2, JNK and p38 signaling and NFκB activation. In addition, IAPs also contribute to LPS-induction of CD80/CD86 costimulatory molecules. Overall, my results suggest that both IAPs and Bcl2 families contribute to survival of human macrophages and that IAPs are also involved in innate immune responses. Unraveling the mechanisms that control macrophage survival and function in various settings would provide therapeutic strategies aimed at eliminating cells when their survival is no longer beneficial for the host, as in the case of HIV infection or autoimmune diseases.

abstract: The communication of genetic material with biomolecules has been a major interest in cancer biology research for decades. Among its different levels of involvement, DNA is known to be a target of several antitumor agents. Additionally, tissue specific interaction between macromolecules such as proteins and structurally important regions of DNA has been reported to define the onset of certain types of cancers. Illustrated in Chapter 1 is the general history of research on the interaction of DNA and anticancer drugs, most importantly different congener of bleomycin (BLM). Additionally, several synthetic analogues of bleomycin, including the structural components and functionalities, are discussed. Chapter 2 describes a new approach to study the double-strand DNA lesion caused by antitumor drug bleomycin. The hairpin DNA library used in this study displays numerous cleavage sites demonstrating the versatility of bleomycin interaction with DNA. Interestingly, some of those cleavage sites suggest a novel mechanism of bleomycin interaction, which has not been reported before. Cytidine methylation has generally been found to decrease site-specific cleavage of DNA by BLM, possibly due to structural change and subsequent reduced bleomycin-mediated recognition of DNA. As illustrated in Chapter 3, three hairpin DNAs known to be strongly bound by bleomycin, and their methylated counterparts, were used to study the dynamics of bleomycin-induced degradation of DNAs in cancer cells. Interestingly, cytidine methylation on one of the DNAs has also shown a major shift in the intensity of bleomycin induced double-strand DNA cleavage pattern, which is known to be a more potent form of bleomycin induced cleavages. DNA secondary structures are known to play important roles in gene regulation. Chapter 4 demonstrates a structural change of the BCL2 promoter element as a result of its dynamic interaction with the individual domains of hnRNP LL, which is essential to facilitate the transcription of BCL2. Furthermore, an in vitro protein synthesis technique has been employed to study the dynamic interaction between protein domains and the i-motif DNA within the promoter element. Several constructs were made involving replacement of a single amino acid with a fluorescent analogue, and these were used to study FRET between domain 1 and the i-motif, the later of which harbored a fluorescent acceptor nucleotide analogue. / Dissertation/Thesis / Doctoral Dissertation Chemistry 2014

Les leucémies aiguës myéloblastiques (LAM) sont des maladies hématopoïétiques caractérisées par une prolifération incontrôlée de précurseurs myéloïdes bloqués à divers stades de différenciation. Le pronostic des LAM reste sombre à cause de la résistance aux traitements et des rechutes après rémission. En conséquence, des thérapies moins intensives et mieux tolérées doivent être développées ; ceci nécessite le développement de stratégies combinatoires associant des molécules avec des modes d’action différents pour augmenter l’efficacité des traitements. Plusieurs approches sont en cours d’étude préclinique et clinique [inhibiteurs des voies de signalisation PI3K/Akt/mTOR, anticorps monoclonaux couplés à une drogue (Mylotarg®), inhibiteurs du protéasome (bortezomib)…] Des travaux récents ont relancé l’intérêt de l’étude des molécules d’origine naturelle pour le traitement des cancers. Ainsi, l’acide flavone-8-acétique (FAA) a suscité de nombreux espoirs au vu de son action sur les tumeurs greffées chez la souris ; il s’est néanmoins révélé inactif chez l’homme du fait d’une métabolisation différente de celle de la souris. L’objectif de ma thèse a été d’étudier les effets d’anticorps monoclonaux dirigés contre l’antigène tumoral CD13 (aminopeptidase-N) et de deux dérivés de FAA, la 2’,3-Dinitroflavone-8-acétique (DNFAA ; inhibiteur de l’activité enzymatique de CD13) et la 3,3’-Diamino-4’-méthoxyflavone (DD1) dans les LAM. Mon étude a montré que DNFAA n’affecte ni la prolifération ni la survie des cellules de LAM (lignées et cellules primaires). Cependant, le traitement de ces cellules par les anticorps anti-CD13, (MY7, SJ1D1, WM15 ; reconnaissant ou non le site enzymatique) induit l’apoptose en activant les voies extrinsèque et intrinsèque. Dans la voie intrinsèque, les anti-CD13 régulent négativement l’expression des protéines anti-apoptotiques Bcl-2 et Mcl-1 et positivement l’expression de la protéine pro-apoptotique Bax. De plus, l’activation de la voie PI3K/Akt apparaît associée au processus apoptotique. Mon étude sur les effets du 3,3’-Diamino-4’-méthoxyflavone dans les cellules de LAM montre une induction d’apoptose résultant de la convergence de l’inhibition du protéasome et de l’activation des voies extrinsèque et intrinsèque. Les cibles de DD1 sont le protéasome, la kinase p70S6K (kinase en aval de mTOR), et les protéines pro-apoptotiques Bad et Bax. De plus, j’ai mis en évidence la dégradation de p70S6K sous l’action de la caspase 3, par le traitement avec DD1, nouvelle propriété partagée par DD1 et le bortezomib. En conclusion, mon travail a permis de mettre en évidence les capacités à induire in vitro des voies d’apoptose déficientes dans les cellules de LAM, d’anticorps monoclonaux anti-CD13 et de la flavone originale, 3,3’-Diamino-4’-methoxyflavone, en tant que nouvel inhibiteur du protéasome. Les propriétés de ces agents pro-apoptotiques méritent d’être analysées de façon plus approfondie. / Acute Myeloid Leukaemia (AML) is a deadly disease characterized by the clonal expansion and accumulation of hematopoietic stem cells arrested at various stages of development. Clinical research efforts are currently focusing on targeted therapies that induce apoptosis in AML cells such as PI3K/Akt/mTOR pathway inhibitors, monoclonal antibodies (Mylotarg®), proteasome inhibitor (bortezomib)… Natural products such as flavonoids have been reported as anticancer agents due to their antioxidant properties as well as to their possible interactions with signalling cascades. Therefore, flavone-8-acetic acid (FAA) has raised considerable attention since the discovery of its exceptional activity on several murine solid tumours. Unfortunately, these promising properties were not confirmed on human due to differential metabolization between human and mouse. The aim of my PhD was to study effects of monoclonal antibody against aminopeptide-N/CD13 and FAA derivatives, 2’,3-Dinitroflavone-8-acetic (DNFAA ; APN/CD13 inhibitor) and 3,3’-Diamino-4’-methoxyflavone (DD1) on acute myeloid leukaemia cells. My studies have shown that DNFAA does not modify proliferation or survival of LAM primary and cell lines. However, treatment of these cells by CD13 antibodies (MY7, SJ1D1 and WM15) induces apoptosis by triggering extrinsic and intrinsic apoptotic pathways. Regarding the intrinsic pathway, anti-CD13 down-regulate anti-apoptotic proteins Bcl-2 and Mcl-1 and up-regulate the pro-apoptotic protein Bax. Morever, PI3K/Akt signalling pathway seems to be associated with this apoptosis. My study about 3,3’-Diamino-4’-methoxyflavone effects on LAM cells has shown that DD1 induces apoptosis by proteasome inhibition and intrinsic and extrinsic pathways induction. DD1 targets p70S6 kinase (a downstream kinase of mTOR) and pro-apoptotic proteins Bad and Bax. Moreover, I have shown p70S6K degradation by caspase 3 during DD1 treatment, a new characteristic shared by DD1 and Bortezomib. As a conclusion, my works demonstrated that CD13 antibodies and a new synthetic flavone are able to induce apoptosis signalling pathway normally impaired on AML cells. Characteristics of these agents deserve to be more deeply analyzed.

Macrophages represent long lived immune cells that are remarkably resistant to apoptosis, which allows them to perform in highly stressful environments. Apoptosis resistance is a characteristic that develops during the differentiation process from monocytes to macrophages. However, the signaling pathways that mediate the development of macrophage antiapoptotic phenotype during differentiation remain mostly unknown. Because of their decreased susceptibility to cell death, macrophages are also key viral reservoirs during HIV infection. My research aims to understand the molecular mechanisms and signaling pathways that mediate cell survival during and after monocyte to macrophage differentiation and the involvement of the main families of antiapoptotic proteins, IAPs (inhibitors of apoptosis) and Bcl2 in this process. HIV accessory protein Vpr was used as an apoptotic stimulus, due to its death inducing abilities in other cell types. My results show that survival of macrophages is distinctively regulated during and after differentiation. I have identified a signaling pathway consisting of PI3K/Akt activation of NFκB that is important in survival of differentiating macrophages by specifically sustaining antiapoptotic Bcl-xL expression. However, once differentiated, Mcl-1, but not Bcl-xL is dependent on PI3K/Akt activation. Moreover, differentiated macrophages are resistant to the effect of HIV-Vpr, which is highly apoptotic for monocytes. In contrast, resistance to HIV-Vpr induced apoptosis of human macrophages is specifically mediated by antiapoptotic IAP proteins, with no involvement of the Bcl2 family, which maintains macrophage viability in the absence of any apoptotic stimuli. In addition to their antiapoptotic properties, IAPs are also important regulators of macrophage function. By using chemical compounds (SMAC mimetics) that target IAPs for degradation, I have shown that IAPs positively modulate LPS-induced IL10, IL-27 and MIG (monokine induced by IFNγ) production in human macrophages, by promoting TRAF2, JNK and p38 signaling and NFκB activation. In addition, IAPs also contribute to LPS-induction of CD80/CD86 costimulatory molecules. Overall, my results suggest that both IAPs and Bcl2 families contribute to survival of human macrophages and that IAPs are also involved in innate immune responses. Unraveling the mechanisms that control macrophage survival and function in various settings would provide therapeutic strategies aimed at eliminating cells when their survival is no longer beneficial for the host, as in the case of HIV infection or autoimmune diseases.

Murine embryonic stem (ES) cells are derived from the inner cell mass of the developing embryonic blastocyst. These cells can self renew which allows them to be propagated indefinitely in the laboratory and they can differentiate into cell types derived from all three germ layers. Manipulation of the mouse genome using gene targeting techniques in conjunction with ES cell technology has provided valuable insights into embryonic development and cell lineage specification. KIT is a trans-membrane receptor tyrosine kinase (RTK) that dimerises upon binding to its ligand, stem cell factor (SCF) resulting in the auto-phosphorylation of intracellular kinase domains. This activity is crucial for the transmission of signals from the cell surface to the nucleus. KIT is expressed on stem and progenitor cells of many lineages and defects in the SCF/KIT signaling pathway causes detrimental effects at both the cellular and physiological level. This project aimed to investigate the role of the SCF/KIT signalling pathway during murine ES cell differentiation and survival. To assess the role of SCF/KIT signalling in ES cell proliferation and survival, we knocked out the c-kit gene in mouse ES cells to produce heterozygous (KitW-lacZ/+) and KIT Null (KitW-lacZ/W-lacZ) cell lines. The self renewal and differentiation profile of these cell lines revealed an auxiliary role for SCF/KIT during ES cell self renewal and an absolute role in survival upon in vitro differentiation. This phenotype of apoptosis upon differentiation was recapitulated in wild type E14 ES cells treated with a KIT neutralising antibody (ACK2). Wild type cells that were treated with the JNK inhibitor, SP600125 had a comparable phenotype to KIT null cells indicating that this could be one of the mediators of KIT signalling that has a protective role in the survival of differentiating ES cells. We hypothesised that blocking classical apoptotic pathways might prevent the death on differentiation observed in KIT null cells. However, neither blocking the pro-apoptotic P38 pathway with the chemical inhibitor PD169316 nor over-expressing the pro-survival protein BCL2 in KIT Null cells could prevent their apoptosis upon differentiation phenotype. This strongly suggests that these pathways are not involved in KIT mediated survival of differentiating ES cells. Although compensatory mechanisms are thought to exist for defective KIT signaling in vivo, an absolute role is assigned to KIT during ES cell differentiation. Further analysis of micro array data comparing gene expression from wild type E14 and KIT Null cell lines may reveal the specific mechanisms of KIT mediated survival during differentiation onset.